Teligent, Inc. (TLGTQ)

OTCMKTS: TLGTQ · Delayed Price · USD
0.0000 (0.00%)
Jan 25, 2022 12:00 AM EST - Market closed

Company Description

Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada.

The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets.

The company's topical semi-solid and liquid products are used in various applications that range from cosmetics and cosmeceuticals; and the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema.

It sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015.

Teligent, Inc. was incorporated in 1977 and is based in Buena, New Jersey. On October 14, 2021, Teligent, Inc. along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Teligent, Inc.
CountryUnited States
IndustryDrug Manufacturers-Specialty & Generic
SectorHealth Care
CEOTimothy Sawyer

Contact Details

105 Lincoln Avenue
Buena, New Jersey 08310
United States
Phone856 697 1441

Stock Details

Ticker SymbolTLGTQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0000352998

Key Executives

Philip K. Yachmetz J.D.Executive Officer
Alyssa LozynskiInterim Chief Financial Officer
Joseph BeneschPrincipal Accounting Officer
Nadya LawrenceSenior Vice President of Technical Services
Justine KostkaAssistant Controller
Ernest Robert De Paolantonio CPA, CPA, M.B.A., MBAExecutive Officer
Vladimir KasparovChief Restructuring Officer
Dr. Subhash SaxenaTechnical Consultant and Member of Scientific Advisory Board

Latest SEC Filings

Oct 27, 202125-NSENotification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Oct 15, 20218-KCurrent report
Oct 8, 20213Initial statement of beneficial ownership of securities
Oct 7, 20213Initial statement of beneficial ownership of securities
Sep 27, 20218-KCurrent report
Sep 24, 20218-KCurrent report
Aug 16, 202110-QQuarterly report [Sections 13 or 15(d)]
Jul 22, 20214Statement of changes in beneficial ownership of securities
Jul 22, 20214Statement of changes in beneficial ownership of securities
Jul 22, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings